Beyond the Guidelines for CMV: Clinical Perspectives on Challenging Cases Post-Transplant

Program Overview

Cytomegalovirus (CMV) is one of the most common and potentially deadly viral pathogens in transplant patients. The management of CMV in transplant is often complex due to toxicities from traditional antiviral therapies, as well as refractory and drug-resistant disease.

Join our distinguished panel as they provide insights on incorporating newer CMV antiviral therapy into clinical practice for transplant care. Do not miss this opportunity to learn more about CMV post-transplant and challenge your clinical skills with patient cases presented by the experts.

JW Marriott Los Angeles L.A. Live

Los Angeles, CA, 90015
October 16, 2024, 11:00 AM PT

You must be registered for IDWeek™ 2024 to attend this symposium.

1.5 CE Credit(s)

Target Audience

Infectious disease, transplantation, internal medicine, and nephrology clinicians

Educational Objectives

Upon completion of this activity, participants should be better able to:

Apply treatment strategies for cytomegalovirus (CMV) infection in transplant recipients
Identify refractory or drug-resistant CMV in transplant recipients in the post-transplant setting
Integrate new antiviral therapies into management regimens for transplant recipients, including those who develop refractory or drug-resistant CMV

Activity Faculty

Emily A. Blumberg, MD

Specialist, Transplant Infectious Diseases
Director, Transplant Infectious Diseases
Program Director, Infectious Diseases Fellowship
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA

Marcus R. Pereira, MD, MPH, FAST

Associate Professor, Medicine
Medical Director, Transplant Infectious Diseases Program
Columbia University Irving Medical Center
NewYork-Presbyterian Hospital
New York, NY

Supporter Statement

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. 

Provider Statement

Provided by RMEI Medical Education, LLC

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Emily A. Blumberg, MD, has relevant financial relationship(s) with Merck, Scynexis, Takeda (Grant Research Support).

Marcus R. Pereira, MD, MPH, FAST, has relevant financial relationship(s) with AstraZeneca, Takeda (Speaker); Synklino (Consultant).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers

RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-24-007-L01-P)
Type of Activity: Knowledge

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Method of Participation and Request for Credit

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be e-mailed to you within 3 weeks. If you have questions regarding the receipt of your e-mailed certificate, please contact RMEI via e-mail at [email protected].

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

Featured RMEI CE Activities